Browsing by Author "Liberman, UA"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- ItemTen years' experience with alendronate for osteoporosis in postmenopausal women(MASSACHUSETTS MEDICAL SOC, 2004) Bone, HG; Hosking, D; Devogelaer, J; Tucci, JR; Emkey, RD; Tonino, RP; Rodriguez Portales, JA; Downs, RW; Gupta, J; Santora, AC; Liberman, UA; Alendronate Phase II OsteoporosisBackground: Antiresorptive agents are widely used to treat osteoporosis. We report the results of a multinational randomized, double-blind study, in which postmenopausal women with osteoporosis were treated with alendronate for up to 10 years.
- ItemTwo-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids - A randomized, double-blind, placebo-controlled extension trial(2001) Adachi, JD; Saag, KG; Delmas, PD; Liberman, UA; Emkey, RD; Seeman, E; Lane, NE; Kaufman, JM; Poubelle, PEE; Hawkins, F; Correa-Rotter, R; Menkes, CJ; Rodriguez-Portales, JA; Schnitzer, TJ; Block, JA; Wing, J; McIlwain, HH; Westhovens, R; Brown, J; Melo-Gomes, JA; Gruber, BL; Yanover, MJ; Leite, MOR; Siminoski, KG; Nevitt, MC; Sharp, JT; Malice, MP; Dumortier, T; Czachur, M; Carofano, W; Daifotis, AObjective. To evaluate the continued efficacy and safety of alendronate (ALN) for up to 2 years in patients receiving glucocorticoids.